AN2 Therapeutics, Inc. (ANTX)
3.61
+0.47
(+14.97%)
USD |
NASDAQ |
Apr 17, 16:00
3.62
+0.01
(+0.28%)
After-Hours: 20:00
AN2 Therapeutics Research and Development Expense (Quarterly) : 6.879M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Relmada Therapeutics, Inc. | 8.072M |
| ACADIA Pharmaceuticals, Inc. | 84.76M |
| Alnylam Pharmaceuticals, Inc. | 372.22M |
| Savara, Inc. | 20.90M |
| BioMarin Pharmaceutical, Inc. | 192.41M |